Edwards Lifesciences Corp. Earnings Dividend

Edwards Lifesciences Corp.’s revenue jumped 16.7% since last year same period to $1648.6Mn in the Q1 2026. On a quarterly growth basis, Edwards Lifesciences Corp. has generated 5.03% jump in its revenue since last 3-months.

Edwards Lifesciences Corp.’s net profit jumped 6.34% since last year same period to $380.7Mn in the Q1 2026. On a quarterly growth basis, Edwards Lifesciences Corp. has generated 317.43% jump in its net profits since last 3-months.

Edwards Lifesciences Corp.’s net profit margin fell -8.88% since last year same period to 23.09% in the Q1 2026. On a quarterly growth basis, Edwards Lifesciences Corp. has generated 297.43% jump in its net profit margins since last 3-months.

Edwards Lifesciences Corp.’s price-to-earnings ratio after this Q1 2026 earnings stands at 45.39.

Edwards Lifesciences Corp.’s earning per share (EPS) estimates for the current quarter stand at 0.68 - a 10.05% jump from last quarter’s estimates.

Edwards Lifesciences Corp.’s earning per share (EPS) estimates for the current year stand at 0.68.

Edwards Lifesciences Corp.’s earning per share (EPS) jumped 21.88% since last year same period to 0.78 in the Q1 2026. This indicates that the Edwards Lifesciences Corp. has generated 21.88% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Edwards Lifesciences Corp.’s return on assets (ROA) stands at 0.08.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Edwards Lifesciences Corp.’s return on equity (ROE) stands at 0.1.